NCT05142254View on ClinicalTrials.gov

A Trial for Prevention of Recurrent Ischemic Priapism in Men With Sickle Cell Disease: A Pilot Study

PHASE2CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

April 1, 2022

Primary Completion Date

July 10, 2023

Study Completion Date

November 9, 2023

Conditions
Priapism Due to Sickle Cell Disease
Interventions
DRUG

Tadalafil

2.5-5 mg/day

DRUG

Hydroxyurea

20 mg/kg/day

DRUG

Placebo

identical placebo to tadalafil created by Bond Biochemical, who is manufacturing the tadalafil as well.

Trial Locations (2)

Unknown

Aminu Kano Teaching Hospital, Kano

Murtala Mohammed Specialist Hospital, Kano

All Listed Sponsors
lead

Vanderbilt University Medical Center

OTHER